<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240213011222&amp;v=2.18.0&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240213011222&amp;v=2.18.0&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Tue, 13 Feb 2024 06:12:23 +0000</lastbuilddate>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Multimodal Imaging Evidence for Optimized Blood Pressure Control Following Hypertensive Pregnancy: Mechanistic Insights Into Beneficial Cardiac Remodeling From the POP-HT Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):542-544. doi: 10.1161/CIRCULATIONAHA.124.068282. Epub 2024 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38346108</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068282>10.1161/CIRCULATIONAHA.124.068282</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346108</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Kerryn W Reding</dc:creator>
<dc:creator>Jennifer H Jordan</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Multimodal Imaging Evidence for Optimized Blood Pressure Control Following Hypertensive Pregnancy: Mechanistic Insights Into Beneficial Cardiac Remodeling From the POP-HT Trial</dc:title>
<dc:identifier>pmid:38346108</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068282</dc:identifier>
</item>
<item>
<title>The Feminine Face of Heart Disease 2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346107/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):489-491. doi: 10.1161/CIRCULATIONAHA.123.064460. Epub 2024 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346107/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38346107</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064460>10.1161/CIRCULATIONAHA.123.064460</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346107</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Nanette K Wenger</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Feminine Face of Heart Disease 2024</dc:title>
<dc:identifier>pmid:38346107</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064460</dc:identifier>
</item>
<item>
<title>Defining the Actionable Items in Women and Heart Disease: A Conversation With Nanette K. Wenger, MD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):492-497. doi: 10.1161/CIRCULATIONAHA.124.068658. Epub 2024 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38346106</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068658>10.1161/CIRCULATIONAHA.124.068658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346106</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Maryjane Farr</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Defining the Actionable Items in Women and Heart Disease: A Conversation With Nanette K. Wenger, MD</dc:title>
<dc:identifier>pmid:38346106</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068658</dc:identifier>
</item>
<item>
<title>Eighth Annual Go Red for Women Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346105/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):487-488. doi: 10.1161/CIRCULATIONAHA.124.068737. Epub 2024 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346105/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38346105</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068737>10.1161/CIRCULATIONAHA.124.068737</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346105</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>Sana M Al-Khatib</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Eighth Annual Go Red for Women Issue</dc:title>
<dc:identifier>pmid:38346105</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068737</dc:identifier>
</item>
<item>
<title>Opportunities in the Postpartum Period to Reduce Cardiovascular Disease Risk After Adverse Pregnancy Outcomes: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346104/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>Adverse pregnancy outcomes are common among pregnant individuals and are associated with long-term risk of cardiovascular disease. Individuals with adverse pregnancy outcomes also have an increased incidence of cardiovascular disease risk factors after delivery. Despite this, evidence-based approaches to managing these patients after pregnancy to reduce cardiovascular disease risk are lacking. In this scientific statement, we review the current evidence on interpregnancy and postpartum...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):e330-e346. doi: 10.1161/CIR.0000000000001212. Epub 2024 Feb 12.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Adverse pregnancy outcomes are common among pregnant individuals and are associated with long-term risk of cardiovascular disease. Individuals with adverse pregnancy outcomes also have an increased incidence of cardiovascular disease risk factors after delivery. Despite this, evidence-based approaches to managing these patients after pregnancy to reduce cardiovascular disease risk are lacking. In this scientific statement, we review the current evidence on interpregnancy and postpartum preventive strategies, blood pressure management, and lifestyle interventions for optimizing cardiovascular disease using the American Heart Association Life's Essential 8 framework. Clinical, health system, and community-level interventions can be used to engage postpartum individuals and to reach populations who experience the highest burden of adverse pregnancy outcomes and cardiovascular disease. Future trials are needed to improve screening of subclinical cardiovascular disease in individuals with a history of adverse pregnancy outcomes, before the onset of symptomatic disease. Interventions in the fourth trimester, defined as the 12 weeks after delivery, have great potential to improve cardiovascular health across the life course.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346104/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38346104</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001212>10.1161/CIR.0000000000001212</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346104</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jennifer Lewey</dc:creator>
<dc:creator>Theresa M Beckie</dc:creator>
<dc:creator>Haywood L Brown</dc:creator>
<dc:creator>Susan D Brown</dc:creator>
<dc:creator>Vesna D Garovic</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Eliza C Miller</dc:creator>
<dc:creator>Garima Sharma</dc:creator>
<dc:creator>Laxmi S Mehta</dc:creator>
<dc:creator>American Heart Association Cardiovascular Disease and Stroke in Women and Underrepresented Populations Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Opportunities in the Postpartum Period to Reduce Cardiovascular Disease Risk After Adverse Pregnancy Outcomes: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38346104</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001212</dc:identifier>
</item>
<item>
<title>Machine Learning for Myocardial Infarction Compared With Guideline-Recommended Diagnostic Pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38344871/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>CONCLUSIONS: CoDE-ACS performs consistently irrespective of the timing of serial cardiac troponin measurement, identifying more patients as low probability with comparable performance to guideline-recommended pathways for MI. Whether care guided by probabilities can improve the early diagnosis of MI requires prospective evaluation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066917. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Collaboration for the Diagnosis and Evaluation of Acute Coronary Syndrome (CoDE-ACS) is a validated clinical decision support tool that uses machine learning with or without serial cardiac troponin measurements at a flexible time point to calculate the probability of myocardial infarction (MI). How CoDE-ACS performs at different time points for serial measurement and compares with guideline-recommended diagnostic pathways that rely on fixed thresholds and time points is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with possible MI without ST-segment-elevation were enrolled at 12 sites in 5 countries and underwent serial high-sensitivity cardiac troponin I concentration measurement at 0, 1, and 2 hours. Diagnostic performance of the CoDE-ACS model at each time point was determined for index type 1 MI and the effectiveness of previously validated low- and high-probability scores compared with guideline-recommended European Society of Cardiology (ESC) 0/1-hour, ESC 0/2-hour, and High-STEACS (High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome) pathways.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 4105 patients (mean age, 61 years [interquartile range, 50-74]; 32% women) were included, among whom 575 (14%) had type 1 MI. At presentation, CoDE-ACS identified 56% of patients as low probability, with a negative predictive value and sensitivity of 99.7% (95% CI, 99.5%-99.9%) and 99.0% (98.6%-99.2%), ruling out more patients than the ESC 0-hour and High-STEACS (25% and 35%) pathways. Incorporating a second cardiac troponin measurement, CoDE-ACS identified 65% or 68% of patients as low probability at 1 or 2 hours, for an identical negative predictive value of 99.7% (99.5%-99.9%); 19% or 18% as high probability, with a positive predictive value of 64.9% (63.5%-66.4%) and 68.8% (67.3%-70.1%); and 16% or 14% as intermediate probability. In comparison, after serial measurements, the ESC 0/1-hour, ESC 0/2-hour, and High-STEACS pathways identified 49%, 53%, and 71% of patients as low risk, with a negative predictive value of 100% (99.9%-100%), 100% (99.9%-100%), and 99.7% (99.5%-99.8%); and 20%, 19%, or 29% as high risk, with a positive predictive value of 61.5% (60.0%-63.0%), 65.8% (64.3%-67.2%), and 48.3% (46.8%-49.8%), resulting in 31%, 28%, or 0, who require further observation in the emergency department, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CoDE-ACS performs consistently irrespective of the timing of serial cardiac troponin measurement, identifying more patients as low probability with comparable performance to guideline-recommended pathways for MI. Whether care guided by probabilities can improve the early diagnosis of MI requires prospective evaluation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00470587.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38344871/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38344871</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066917>10.1161/CIRCULATIONAHA.123.066917</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38344871</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jasper Boeddinghaus</dc:creator>
<dc:creator>Dimitrios Doudesis</dc:creator>
<dc:creator>Pedro Lopez-Ayala</dc:creator>
<dc:creator>Kuan Ken Lee</dc:creator>
<dc:creator>Luca Koechlin</dc:creator>
<dc:creator>Karin Wildi</dc:creator>
<dc:creator>Thomas Nestelberger</dc:creator>
<dc:creator>Raphael Borer</dc:creator>
<dc:creator>Òscar Miró</dc:creator>
<dc:creator>F Javier Martin-Sanchez</dc:creator>
<dc:creator>Ivo Strebel</dc:creator>
<dc:creator>Maria Rubini Giménez</dc:creator>
<dc:creator>Dagmar I Keller</dc:creator>
<dc:creator>Michael Christ</dc:creator>
<dc:creator>Anda Bularga</dc:creator>
<dc:creator>Ziwen Li</dc:creator>
<dc:creator>Amy V Ferry</dc:creator>
<dc:creator>Chris Tuck</dc:creator>
<dc:creator>Atul Anand</dc:creator>
<dc:creator>Alasdair Gray</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Christian Mueller</dc:creator>
<dc:creator>CoDE-ACS and APACE Investigators</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Machine Learning for Myocardial Infarction Compared With Guideline-Recommended Diagnostic Pathways</dc:title>
<dc:identifier>pmid:38344871</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066917</dc:identifier>
</item>
<item>
<title>Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography in the Guidance of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38344859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>CONCLUSIONS: IVI-guided PCI was associated with a reduction in ischemia-driven target lesion revascularization compared with ICA-guided PCI, with the difference most evident for IVUS. In contrast, no significant differences in myocardial infarction were observed between guidance strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.067583. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Results from multiple randomized clinical trials comparing outcomes after intravascular ultrasound (IVUS)- and optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) with invasive coronary angiography (ICA)-guided PCI as well as a pivotal trial comparing the 2 intravascular imaging (IVI) techniques have provided mixed results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Major electronic databases were searched to identify eligible trials evaluating at least 2 PCI guidance strategies among ICA, IVUS, and OCT. The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events. Frequentist random-effects network meta-analyses were conducted. The results were replicated by Bayesian random-effects models. Pairwise meta-analyses of the direct components, multiple sensitivity analyses, and pairwise meta-analyses IVI versus ICA were supplemented.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The results from 24 randomized trials (15 489 patients: IVUS versus ICA, 46.4%, 7189 patients; OCT versus ICA, 32.1%, 4976 patients; OCT versus IVUS, 21.4%, 3324 patients) were included in the network meta-analyses. IVUS was associated with reduced target lesion revascularization compared with ICA (odds ratio [OR], 0.69 [95% CI, 0.54-0.87]), whereas no significant differences were observed between OCT and ICA (OR, 0.83 [95% CI, 0.63-1.09]) and OCT and IVUS (OR, 1.21 [95% CI, 0.92-1.58]). Myocardial infarction did not significantly differ between guidance strategies (IVUS versus ICA: OR, 0.91 [95% CI, 0.70-1.19]; OCT versus ICA: OR, 0.87 [95% CI, 0.68-1.11]; OCT versus IVUS: OR, 0.96 [95% CI, 0.69-1.33]). These results were consistent with the secondary outcomes of ischemia-driven target lesion revascularization, target vessel myocardial infarction, and target vessel revascularization, and sensitivity analyses generally did not reveal inconsistency. OCT was associated with a significant reduction of stent thrombosis compared with ICA (OR, 0.49 [95% CI, 0.26-0.92]) but only in the frequentist analysis. Similarly, the results in terms of survival between IVUS or OCT and ICA were uncertain across analyses. A total of 25 randomized trials (17 128 patients) were included in the pairwise meta-analyses IVI versus ICA where IVI guidance was associated with reduced target lesion revascularization, cardiac death, and stent thrombosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: IVI-guided PCI was associated with a reduction in ischemia-driven target lesion revascularization compared with ICA-guided PCI, with the difference most evident for IVUS. In contrast, no significant differences in myocardial infarction were observed between guidance strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38344859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38344859</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067583>10.1161/CIRCULATIONAHA.123.067583</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38344859</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Claudio Laudani</dc:creator>
<dc:creator>Giovanni Occhipinti</dc:creator>
<dc:creator>Marco Spagnolo</dc:creator>
<dc:creator>Antonio Greco</dc:creator>
<dc:creator>Carla Rochira</dc:creator>
<dc:creator>Federica Agnello</dc:creator>
<dc:creator>Davide Landolina</dc:creator>
<dc:creator>Maria Sara Mauro</dc:creator>
<dc:creator>Simone Finocchiaro</dc:creator>
<dc:creator>Placido Mazzone</dc:creator>
<dc:creator>Nicola Ammirabile</dc:creator>
<dc:creator>Antonino Imbesi</dc:creator>
<dc:creator>Carmelo Raffo</dc:creator>
<dc:creator>Sergio Buccheri</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography in the Guidance of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis</dc:title>
<dc:identifier>pmid:38344859</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067583</dc:identifier>
</item>
<item>
<title>The American Heart Association at 100: A Century of Scientific Progress and the Future of Cardiovascular Science: A Presidential Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38344851/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>In 1924, the founders of the American Heart Association (AHA) envisioned an international society focused on the heart and aimed at facilitating research, disseminating information, increasing public awareness, and developing public health policy related to heart disease. This presidential advisory provides a comprehensive review of the past century of cardiovascular and stroke science, with a focus on the AHA's contributions, as well as informed speculation about the future of cardiovascular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 12. doi: 10.1161/CIR.0000000000001213. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In 1924, the founders of the American Heart Association (AHA) envisioned an international society focused on the heart and aimed at facilitating research, disseminating information, increasing public awareness, and developing public health policy related to heart disease. This presidential advisory provides a comprehensive review of the past century of cardiovascular and stroke science, with a focus on the AHA's contributions, as well as informed speculation about the future of cardiovascular science into the next century of the organization's history. The AHA is a leader in fundamental, translational, clinical, and population science, and it promotes the concept of the "learning health system," in which a continuous cycle of evidence-based practice leads to practice-based evidence, permitting an iterative refinement in clinical evidence and care. This advisory presents the AHA's journey over the past century from instituting professional membership to establishing extraordinary research funding programs; translating evidence to practice through clinical practice guidelines; affecting systems of care through quality programs, certification, and implementation; leading important advocacy efforts at the federal, state and local levels; and building global coalitions around cardiovascular and stroke science and public health. Recognizing an exciting potential future for science and medicine, the advisory offers a vision for even greater impact for the AHA's second century in its continued mission to be a relentless force for longer, healthier lives.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38344851/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38344851</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001213>10.1161/CIR.0000000000001213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38344851</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Donna K Arnett</dc:creator>
<dc:creator>Ivor J Benjamin</dc:creator>
<dc:creator>Robert H Eckel</dc:creator>
<dc:creator>Augustus O Grant</dc:creator>
<dc:creator>Steven R Houser</dc:creator>
<dc:creator>Alice K Jacobs</dc:creator>
<dc:creator>Daniel W Jones</dc:creator>
<dc:creator>Rose Marie Robertson</dc:creator>
<dc:creator>Ralph L Sacco</dc:creator>
<dc:creator>Sidney C Smith</dc:creator>
<dc:creator>Myron L Weisfeldt</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>Mariell Jessup</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The American Heart Association at 100: A Century of Scientific Progress and the Future of Cardiovascular Science: A Presidential Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38344851</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001213</dc:identifier>
</item>
<item>
<title>The Macrophage Landscape Across the Lifespan of a Human Cardiac Allograft</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38344825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>CONCLUSIONS: Our findings reveal an imbalance of donor-derived and recipient-derived macrophages in the pediatric cardiac allograft that contributes to allograft failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.065294. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Much of our knowledge of organ rejection after transplantation is derived from rodent models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used single-nucleus RNA sequencing to investigate the inflammatory myocardial microenvironment in human pediatric cardiac allografts at different stages after transplantation. We distinguished donor- from recipient-derived cells using naturally occurring genetic variants embedded in single-nucleus RNA sequencing data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Donor-derived tissue resident macrophages, which accompany the allograft into the recipient, are lost over time after transplantation. In contrast, monocyte-derived macrophages from the recipient populate the heart within days after transplantation and form 2 macrophage populations: recipient MP1 and recipient MP2. Recipient MP2s have cell signatures similar to donor-derived resident macrophages; however, they lack signatures of pro-reparative phagocytic activity typical of donor-derived resident macrophages and instead express profibrotic genes. In contrast, recipient MP1s express genes consistent with hallmarks of cellular rejection. Our data suggest that recipient MP1s activate a subset of natural killer cells, turning them into a cytotoxic cell population through feed-forward signaling between recipient MP1s and natural killer.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal an imbalance of donor-derived and recipient-derived macrophages in the pediatric cardiac allograft that contributes to allograft failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38344825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38344825</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065294>10.1161/CIRCULATIONAHA.123.065294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38344825</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Xiao Li</dc:creator>
<dc:creator>Diwakar Turaga</dc:creator>
<dc:creator>Rich G Li</dc:creator>
<dc:creator>Chang-Ru Tsai</dc:creator>
<dc:creator>Julianna N Quinn</dc:creator>
<dc:creator>Yi Zhao</dc:creator>
<dc:creator>Ruby Wilson</dc:creator>
<dc:creator>Katherine Carlson</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>Joseph A Spinner</dc:creator>
<dc:creator>Edward J Hickey</dc:creator>
<dc:creator>Iki Adachi</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Macrophage Landscape Across the Lifespan of a Human Cardiac Allograft</dc:title>
<dc:identifier>pmid:38344825</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065294</dc:identifier>
</item>
<item>
<title>Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38344820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 5047 participants with a mean±SD age of 57.2±10.0 years, type 2 diabetes duration of 4.0±2.7 years, and low baseline prevalence of cardiovascular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a median of 5 years. Prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalization or revascularization), MACE-5 (MACE-4+coronary revascularization), MACE-6 (MACE-5+hospitalization for heart failure), and the individual components. MACE outcomes and hospitalization for heart failure in the liraglutide-treated group were compared with the other groups combined using Cox proportional hazards models. MACE-6 was also analyzed as recurrent events using a proportional rate model to compare all treatment groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We observed no statistically significant differences in the cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or their individual components, by randomized treatment group. However, when compared with the other treatment groups combined, the liraglutide-treated group had a significantly lower risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54-0.91]; <i>P</i>=0.021), MACE-6 (adjusted hazard ratio, 0.70 [95% CI, 0.55-0.90]; <i>P</i>=0.021), and hospitalization for heart failure (adjusted hazard ratio, 0.49 [95% CI, 0.28-0.86]; <i>P</i>=0.022). Compared with the liraglutide group, significantly higher rates of recurrent MACE-6 events occurred in the groups treated with glimepiride (rate ratio, 1.61 [95% CI, 1.13-2.29]) or sitagliptin (rate ratio 1.75; [95% CI, 1.24-2.48]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01794143.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38344820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38344820</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066604>10.1161/CIRCULATIONAHA.123.066604</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38344820</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jennifer B Green</dc:creator>
<dc:creator>Brendan M Everett</dc:creator>
<dc:creator>Alokananda Ghosh</dc:creator>
<dc:creator>Naji Younes</dc:creator>
<dc:creator>Heidi Krause-Steinrauf</dc:creator>
<dc:creator>Joshua Barzilay</dc:creator>
<dc:creator>Cyrus Desouza</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Yashashwi Pokharel</dc:creator>
<dc:creator>David Schade</dc:creator>
<dc:creator>Alexandra Scrymgeour</dc:creator>
<dc:creator>Meng H Tan</dc:creator>
<dc:creator>Kristina M Utzschneider</dc:creator>
<dc:creator>Sunder Mudaliar</dc:creator>
<dc:creator>GRADE Study Research Group</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)</dc:title>
<dc:identifier>pmid:38344820</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066604</dc:identifier>
</item>
<item>
<title>CEO Foreword: The Centennial Presidential Advisory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38344807/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.124.068162. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38344807/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38344807</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068162>10.1161/CIRCULATIONAHA.124.068162</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38344807</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Nancy Brown</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>CEO Foreword: The Centennial Presidential Advisory</dc:title>
<dc:identifier>pmid:38344807</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068162</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: Floris Heinen, MD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38340018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae077. doi: 10.1093/eurheartj/ehae077. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38340018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38340018</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae077>10.1093/eurheartj/ehae077</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38340018</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: Floris Heinen, MD</dc:title>
<dc:identifier>pmid:38340018</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae077</dc:identifier>
</item>
<item>
<title>The obesity syndemic in the European community: towards a systems thinking approach for preventive policies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38339964/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae066. doi: 10.1093/eurheartj/ehae066. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38339964/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38339964</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae066>10.1093/eurheartj/ehae066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38339964</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Gema Frühbeck</dc:creator>
<dc:creator>Luca Busetto</dc:creator>
<dc:creator>Federico Carbone</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The obesity syndemic in the European community: towards a systems thinking approach for preventive policies</dc:title>
<dc:identifier>pmid:38339964</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae066</dc:identifier>
</item>
<item>
<title>Cardiac cryptographers: cracking the code of the epitranscriptome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38339963/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae057. doi: 10.1093/eurheartj/ehae057. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38339963/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38339963</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae057>10.1093/eurheartj/ehae057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38339963</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Charles P Rabolli</dc:creator>
<dc:creator>Federica Accornero</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac cryptographers: cracking the code of the epitranscriptome</dc:title>
<dc:identifier>pmid:38339963</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae057</dc:identifier>
</item>
<item>
<title>Advancing cardiovascular research: Gemma Vilahur talks about her pioneering heart health discoveries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38339914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae034. doi: 10.1093/eurheartj/ehae034. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38339914/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38339914</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae034>10.1093/eurheartj/ehae034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38339914</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Advancing cardiovascular research: Gemma Vilahur talks about her pioneering heart health discoveries</dc:title>
<dc:identifier>pmid:38339914</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae034</dc:identifier>
</item>
<item>
<title>Urgent need to define unmet medical needs in cardiovascular diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38339912/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae041. doi: 10.1093/eurheartj/ehae041. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38339912/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38339912</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae041>10.1093/eurheartj/ehae041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38339912</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Piotr Szymański</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Urgent need to define unmet medical needs in cardiovascular diseases</dc:title>
<dc:identifier>pmid:38339912</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae041</dc:identifier>
</item>
<item>
<title>Impact of topology on the number of loops during macro-re-entrant atrial tachycardia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38339877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae032. doi: 10.1093/eurheartj/ehae032. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38339877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38339877</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae032>10.1093/eurheartj/ehae032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38339877</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Nele Vandersickel</dc:creator>
<dc:creator>Sander Hendrickx</dc:creator>
<dc:creator>Robin Van den Abeele</dc:creator>
<dc:creator>Bjorn Verstraeten</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Impact of topology on the number of loops during macro-re-entrant atrial tachycardia</dc:title>
<dc:identifier>pmid:38339877</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae032</dc:identifier>
</item>
<item>
<title>How artificial intelligence can assist with ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38339876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 10:ehae030. doi: 10.1093/eurheartj/ehae030. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38339876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38339876</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae030>10.1093/eurheartj/ehae030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38339876</guid>
<pubDate>Sat, 10 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jamol Uzokov</dc:creator>
<dc:creator>Anis Alyavi</dc:creator>
<dc:creator>Bakhromkhon Alyavi</dc:creator>
<dc:creator>Akbar Abdullaev</dc:creator>
<dc:date>2024-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>How artificial intelligence can assist with ischaemic heart disease</dc:title>
<dc:identifier>pmid:38339876</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae030</dc:identifier>
</item>
<item>
<title>Retraction of: Age-Induced Accumulation of Succinate Promotes Cardiac Fibrogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38333982/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 9. doi: 10.1161/RES.0000000000000663. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38333982/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38333982</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000663>10.1161/RES.0000000000000663</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38333982</guid>
<pubDate>Fri, 09 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Retraction of: Age-Induced Accumulation of Succinate Promotes Cardiac Fibrogenesis</dc:title>
<dc:identifier>pmid:38333982</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000663</dc:identifier>
</item>
<item>
<title>Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38328945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>CONCLUSIONS: Diffuse RV uptake of bone tracer on SPECT imaging is associated with poor outcomes in patients with ATTR-CM and is an independent prognostic marker at diagnosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.066524. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients with ATTR-CM who underwent diagnostic bone tracer scintigraphy with acquisition of whole-body planar and cardiac single-photon emission computed tomography (SPECT) images from the National Amyloidosis Centre and 4 Italian centers were included. Cardiac uptake was defined according to the Perugini classification: 0=absent cardiac uptake; 1=mild uptake less than bone; 2=moderate uptake equal to bone; and 3=high uptake greater than bone. Extent of right ventricular (RV) uptake was defined as focal (basal segment of the RV free wall only) or diffuse (extending beyond basal segment) on the basis of SPECT imaging. The primary outcome was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1422 patients with ATTR-CM, RV uptake accompanying left ventricular uptake was identified by SPECT imaging in 100% of cases at diagnosis. Median follow-up in the whole cohort was 34 months (interquartile range, 21 to 50 months), and 494 patients died. By Kaplan-Meier analysis, diffuse RV uptake on SPECT imaging (n=936) was associated with higher all-cause mortality compared with focal (n=486) RV uptake (77.9% versus 22.1%; <i>P</i>&lt;0.001), whereas Perugini grade was not associated with survival (<i>P</i>=0.27 in grade 2 versus grade 3). On multivariable analysis, after adjustment for age at diagnosis (hazard ratio [HR], 1.03 [95% CI, 1.02-1.04]; <i>P</i>&lt;0.001), presence of the p.(V142I) TTR variant (HR, 1.42 [95% CI, 1.20-1.81]; <i>P</i>=0.004), National Amyloidosis Centre stage (each category, <i>P</i>&lt;0.001), stroke volume index (HR, 0.99 [95% CI, 0.97-0.99]; <i>P</i>=0.043), E/e' (HR, 1.02 [95% CI, 1.007-1.03]; <i>P</i>=0.004), right atrial area index (HR, 1.05 [95% CI, 1.02-1.08]; <i>P</i>=0.001), and left ventricular global longitudinal strain (HR, 1.06 [95% CI, 1.03-1.09]; <i>P</i>&lt;0.001), diffuse RV uptake on SPECT imaging (HR, 1.60 [95% CI, 1.26-2.04]; <i>P</i>&lt;0.001) remained an independent predictor of all-cause mortality. The prognostic value of diffuse RV uptake was maintained across each National Amyloidosis Centre stage and in both wild-type and hereditary ATTR-CM (<i>P</i>&lt;0.001 and <i>P</i>=0.02, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diffuse RV uptake of bone tracer on SPECT imaging is associated with poor outcomes in patients with ATTR-CM and is an independent prognostic marker at diagnosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38328945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38328945</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066524>10.1161/CIRCULATIONAHA.123.066524</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38328945</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Christian Gagliardi</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Linda Pagura</dc:creator>
<dc:creator>Giacomo Tini</dc:creator>
<dc:creator>Franca Dore</dc:creator>
<dc:creator>Rachele Bonfiglioli</dc:creator>
<dc:creator>Matteo Bauckneht</dc:creator>
<dc:creator>Alberto Miceli</dc:creator>
<dc:creator>Francesca Girardi</dc:creator>
<dc:creator>Anna Lisa Martini</dc:creator>
<dc:creator>Giulia Barbati</dc:creator>
<dc:creator>Egidio Natalino Costanzo</dc:creator>
<dc:creator>Angelo Giuseppe Caponetti</dc:creator>
<dc:creator>Andrea Paccagnella</dc:creator>
<dc:creator>Maurizio Sguazzotti</dc:creator>
<dc:creator>Giovanni La Malfa</dc:creator>
<dc:creator>Mattia Zampieri</dc:creator>
<dc:creator>Roberto Sciagrà</dc:creator>
<dc:creator>Federico Perfetto</dc:creator>
<dc:creator>Dorota Rowczenio</dc:creator>
<dc:creator>Janet Gilbertson</dc:creator>
<dc:creator>David F Hutt</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Claudio Rapezzi</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:38328945</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066524</dc:identifier>
</item>
<item>
<title>Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38328928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240213011222&amp;v=2.18.0
      <description>CONCLUSIONS: Our work reveals that the phosphorylation-regulated dynamic phase separation of HIP-55 protects against sympathetic/adrenergic system-mediated heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.067519. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF), which is the terminal stage of many cardiovascular diseases, is associated with low survival rates and a severe financial burden. The mechanisms, especially the molecular mechanism combined with new theories, underlying the pathogenesis of HF remain elusive. We demonstrate that phosphorylation-regulated dynamic liquid-liquid phase separation of HIP-55 (hematopoietic progenitor kinase 1-interacting protein of 55 kDa) protects against HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Fluorescence recovery after photobleaching assay, differential interference contrast analysis, pull-down assay, immunofluorescence, and immunohistochemical analysis were used to investigate the liquid-liquid phase separation capacity of HIP-55 and its dynamic regulation in vivo and in vitro. Mice with genetic deletion of HIP-55 and mice with cardiac-specific overexpression of HIP-55 were used to examine the role of HIP-55 on β-adrenergic receptor hyperactivation-induced HF. Mutation analysis and mice with specific phospho-resistant site mutagenesis were used to identify the role of phosphorylation-regulated dynamic liquid-liquid phase separation of HIP-55 in HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Genetic deletion of HIP-55 aggravated HF, whereas cardiac-specific overexpression of HIP-55 significantly alleviated HF in vivo. HIP-55 possesses a strong capacity for phase separation. Phase separation of HIP-55 is dynamically regulated by AKT-mediated phosphorylation at S269 and T291 sites, failure of which leads to impairment of HIP-55 dynamic phase separation by formation of abnormal aggregation. Prolonged sympathetic hyperactivation stress induced decreased phosphorylation of HIP-55 S269 and T291, dysregulated phase separation, and subsequent aggregate formation of HIP55. Moreover, we demonstrated the important role of dynamic phase separation of HIP-55 in inhibiting hyperactivation of the β-adrenergic receptor-mediated P38/MAPK (mitogen-activated protein kinase) signaling pathway. A phosphorylation-deficient HIP-55 mutation, which undergoes massive phase separation and forms insoluble aggregates, loses the protective activity against HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our work reveals that the phosphorylation-regulated dynamic phase separation of HIP-55 protects against sympathetic/adrenergic system-mediated heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38328928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240213011222&v=2.18.0">38328928</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067519>10.1161/CIRCULATIONAHA.123.067519</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38328928</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Yunqi Jiang</dc:creator>
<dc:creator>Jinge Gu</dc:creator>
<dc:creator>Xiaodou Niu</dc:creator>
<dc:creator>Jiaojiao Hu</dc:creator>
<dc:creator>Yongzhen Zhang</dc:creator>
<dc:creator>Dan Li</dc:creator>
<dc:creator>Yida Tang</dc:creator>
<dc:creator>Cong Liu</dc:creator>
<dc:creator>Zijian Li</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure</dc:title>
<dc:identifier>pmid:38328928</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067519</dc:identifier>
</item>





























</channel>
</rss>